The authors report their experience in treating three men with cabergoline for micro- (one case) and macroprolactinoma (two cases). The clinical aspects plus hormonal and instrumental data prior to treatment are also reported. Clinical and hormonal evaluation was carried out 2, 3 and 6 months after therapy and CT after the sixth month. Results enabled the effectiveness of the drug to be checked.
WebsterJ.: Review comparativa degli studi sulla tollerabilità dei dopamino-agonisti per il trattamento dell'iperprolattinemia e per l'inibizione della lattazione. Drug Safety, 14, 4: 228–238, 1996.
3.
FerrariC., BarbieriC., CalderaR., MucciM., CodecasaF., ParacchiA., RomanoC., BoghenM., DubiniA.: Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab., 63: 941–945, 1986.
4.
FerrariC., ParacchiA., MatteiA.M., De VincentiisS., D'AlbertonA., CrosignaniP.G.: Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol., 126: 489–494, 1992.
5.
WebsterJ., PiscitelliG., PolliA., D'AlbertonA., FalsettiL., FerrariC., FiorettiP., GiordanoG., L'HermiteM., CiccarelliE., CrosignaniP.G., De CeccoL., FadiniR., FagliaG., FlamigniF., TamburranoG., ScanlonM.F. (European multicentre cabergoline dose-finding Study Group): Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double bind, multicentre study. Clin. Endoclinol., 37: 534–541, 1992.
6.
FerrariC., PiscitelliG., CrosignaniP.G.: Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum. Reprod., 10: 101–107, 1995.
